TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Postoperative development of DIC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Target to Background Ratio LAA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time activity curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Vascular Function as Measured by Left CAVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Vascular Function as Measured by Right CAVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Cardiometabolic Risk as Measured by PWV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Cardiometabolic Risk as Measured by RHI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Effect of Pioglitazone on Vascular Inflammation as Measured by TBR Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Successful colon cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Spatial Working Memory Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Trail Making Test: Part A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Trail Making Test: Part B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Thermal sensory thresholds of sensitivity to hot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient's weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Pericarditis Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Influenza Vaccine Coverage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Neuropsychological well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: COPD Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Positive Responses to Palatability Assessment of The Taste of Mesalamine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Detected an Aftertaste of Mesalamine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Willing to Take Mesalamine Via Treatment Method on a Regular Basis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Mean SABA Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Best Objective Response Rate (bORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical and biological controls of bullous pemphigoid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Total Severity Score of vulvovaginal dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Plasma IGF-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: CR Program Adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in proxy-reported general fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: mean percentage of ventricular pacing (2-month period)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean percentage of ventricular pacing (up to 1 year)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Platelet recovery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ease of use of Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Functional natural killer (NK) cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Desaturation during intraoperative period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With PSA < 0.6 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: late lumen loss in-segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change from Baseline 2 in DAS28(CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Film for malaria parasitaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Weight/height ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Contrast-associated acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Emergency contraception knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptomatic effects of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiologic effects of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic effects of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic Visual Field
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the Four Dengue Serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Objective Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of incidents and accidents in sport practice
Endpoint domain: Adverse events/effects
Primary endpoint: Exhaled Breath Temperature (TAE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Difference in Mean in Clinic Systolic BP Between the Active and Vehicle Groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in glandular cellularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (AEs) up to Week 52
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) up to Week 52
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment Emergent AEs Leading to Discontinuation From Study Treatment up to Week 52
Endpoint domain: Adverse events/effects
Primary endpoint: Number of all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: Rate of regrowth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autism screening results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of stroke onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency, type and grade of Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: meconium concentration of buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: meconium concentration of methadone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Self-management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction in Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the curve of atorvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the curve of lisinopril
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the curve of griseofulvin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve of digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Number of Subjects Experiencing at Least One Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Total Number of Subject Withdrawals Due to Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in ESA Dose Required to Maintain Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Becks Depression Inventory Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: severity and frequency of drooling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV infection rates of infants
Endpoint domain: Mortality/survival
Primary endpoint: iMP-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Hypersensitivity
Endpoint domain: Adverse events/effects
Primary endpoint: Patient experience in missing an appointment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Concentration Time Curve From Time Zero to the Time of Last Measured Concentration (96 Hours) (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under The Concentration Time Curve From Zero Through Infinity (AUC∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events causing cessation of session
Endpoint domain: Adverse events/effects
Primary endpoint: Disease-Free Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in unimanual capacity on Upper Extremity Skills Test (QUEST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in manual ability on ABILHAND-Kids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Reintegration Difficulties
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Caregivers quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of Physician's Global COPD Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of FEV1/FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: patient reported functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Nocturnal Polyuria Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent Mucociliary Clearance at 60 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lenke classification of posterolateral fusion success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to work at one year post-program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: change in clinical success/failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flow-mediated dilation of the arteria brachialis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rotator Cuff Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Post-operative functional recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: bioequivalence of ganciclovir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Signs and Symptoms as Measured by ASAS 20 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to relapse after initial local cure
Endpoint domain: Mortality/survival
Primary endpoint: Differential expression of molecular pathways
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response to gluten
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Clearance of Caspofungin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent Event Rate of Grade 3 or Higher Bacterial or Fungal Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Maternal Weight Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Imaging sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of glabellar lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: TIVAD function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Responders at Week 2 and Week 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Metabolic Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUCinf of ABP 501
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of ABP 501
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of Adalimumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Adalimumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolism measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Matrix Metalloproteinase Level in Wound Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Hospitalized Days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mutations associated with outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Subjects Seropositive for Haemagglutination Inhibition (HI) Antibodies Against the A/California Virus Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroconverted (SCR) Subjects for Haemagglutination Inhibition (HI) Antibodies Against A/California Virus Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seroprotected (SPR) Subjects for HI Antibodies Against A/California Virus Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiac Output as Measured by ECOM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum N terminal proBNP (NT-proBNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Lgi3 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients in remission at week 24 from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients in remission at week 24 after dose-reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic progression of total Sharp van der Heijde score after 48 weeks from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence or absence of respiratory viruses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Baseline Pain intensity with Visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Maximum Mouth Opening on Postoperative Follow Up Visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Pain intensity with Visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of the ankle foot orthosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of diabetes screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients with uncontrolled or controlled AAV disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acetoacetate brain uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glucose brain uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improved palliative efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Hemostatic Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction of level of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum voluntary isometric contraction (MVIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HAGOS Sport subscale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cumulative rate of liver decompensation and/or hepatic carcinoma and/or liver related death
Endpoint domain: Mortality/survival
Primary endpoint: Number of Breakthrough cancer Pain (BTcP) episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of F-18-EF5
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in platelet count from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Central systolic blood pressure change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peripheral systolic blood pressure change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incremental cost per quality-adjusted life-years (QALY)
Endpoint domain: Resource use
Primary endpoint: Experience of interventional pain management
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AUCISEC (0-10 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of NL CPT-11
Endpoint domain: Adverse events/effects
Primary endpoint: pharmacokinetics of NL CPT-11
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Preventable Hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Incidence of Middle Meatal Synechiae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ovarian reserve by anti-mullerian hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: LPS levels in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rowe scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proper visualization of vitreous strands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: β-cell endocrine function progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in exhaled nitric oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in sputum differential cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: bond failure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of mapping success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of diagnoses in early, curable stage
Endpoint domain: Mortality/survival
Primary endpoint: Global LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lymph node stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Checklist Individual Strength (CIS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Portion of Study Participants Reporting Greater Utility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of people attending ED with back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Iodinated Contrast Volume used in PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Vaginal Delivery Within 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Fistula position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fistula level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fistula length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Gastrointestinal total symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency of anal HSIL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: bladder innervation quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrochemical skin conductance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Overall Lifting and Tightening of the Jowls and/or Neck Laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: inflammatory cytokines secretion levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes